{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:07:28Z","timestamp":1791572848859,"version":"4.3.4"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Animals"],"abstract":"<jats:p>Feline pulmonary carcinomas are rare and often carry a poor prognosis, particularly when associated with feline lung\u2013digit syndrome. We report a cat with primary pulmonary carcinoma and extensive metastases\u2014including digits, pleura, mandible, scapula, spleen, skeletal muscle, and distant lymph nodes\u2014supporting the broader \u201cMODAL syndrome\u201d concept. Palliative therapy with toceranib phosphate and meloxicam achieved prolonged survival and excellent quality of life, with no adverse effects despite dose escalation. Rapid progression after discontinuation suggests a role for toceranib in delaying tumour growth. Immunohistochemistry revealed c-kit expression in one metastatic lesion but not in the primary tumour or most metastases, highlighting intratumoral heterogeneity and the complexity of targeted therapy. The observed benefit likely reflects toceranib\u2019s multi-target activity (VEGFR2, PDGFR), impacting angiogenesis and tumour progression. This case represents the first report of toceranib phosphate use in feline pulmonary carcinoma and underscores its potential as a palliative option.<\/jats:p>","DOI":"10.3390\/ani16050839","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:27:18Z","timestamp":1773062838000},"page":"839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Feline Lung\u2013Digit Syndrome with Toceranib Phosphate: Prolonged Survival and Novel Metastatic Findings"],"prefix":"10.3390","volume":"16","author":[{"given":"In\u00eas","family":"Cabral","sequence":"first","affiliation":[{"name":"ICBAS-School of Medicine and Biomedical Sciences, Porto University, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0414-3020","authenticated-orcid":false,"given":"Gustavo","family":"Matos","sequence":"additional","affiliation":[{"name":"ICBAS-School of Medicine and Biomedical Sciences, Porto University, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Fernandes Silva","sequence":"additional","affiliation":[{"name":"ICBAS-School of Medicine and Biomedical Sciences, Porto University, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Egas Moniz Centre for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Carvalho","sequence":"additional","affiliation":[{"name":"ICBAS-School of Medicine and Biomedical Sciences, Porto University, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Amorim","sequence":"additional","affiliation":[{"name":"ICBAS-School of Medicine and Biomedical Sciences, Porto University, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Rua J\u00falio Amaral de Carvalho Nr. 45, 4200-804 Porto, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/1098612X12439267","article-title":"FELINE LUNG-DIGIT SYNDROME Unusual Metastatic Patterns of Primary Lung Tumours in Cats","volume":"14","author":"Goldfinch","year":"2012","journal-title":"JFMS Clin. Pract. J. Feline Med. Surg."},{"key":"ref_2","first-page":"2055116917691069","article-title":"Metastatic Pulmonary Carcinomas in Cats (\u2018Feline Lung\u2013Digit Syndrome\u2019): Further Variations on a Theme","volume":"3","author":"Thrift","year":"2017","journal-title":"JFMS Open Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5326\/15473317-36-6-501","article-title":"Metastatic Digital Carcinoma in the Cat: A Retrospective Study of 36 Cats","volume":"36","author":"Gottfried","year":"2000","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bernabe, L.F., Portela, R., Nguyen, S., Kisseberth, W.C., Pennell, M., Yancey, M.F., and London, C.A. (2013). Evaluation of the Adverse Event Profile and Pharmacodynamics of Toceranib Phosphate Administered to Dogs with Solid Tumors at Doses below the Maximum Tolerated Dose. BMC Vet. Res., 9.","DOI":"10.1186\/1746-6148-9-190"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1098612X15622237","article-title":"Retrospective Evaluation of Toceranib Phosphate (Palladia) in Cats with Oral Squamous Cell Carcinoma","volume":"19","author":"Wiles","year":"2017","journal-title":"J. Feline Med. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fonseca-Alves, C.E., Massimini, M., Gentilini, F., Nascimento, Y., and Coelho, B. (2023). Tyrosine Kinase Inhibitors as an Alternative Treatment in Canine Mast Cell Tumor. Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1188795"},{"key":"ref_7","first-page":"751","article-title":"Long-Term Clinical Control of Feline Pancreatic Carcinoma with Toceranib Phosphate","volume":"59","author":"Dedeaux","year":"2018","journal-title":"Can. Vet. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2055116920924911","DOI":"10.1177\/2055116920924911","article-title":"Long-Term Survival in a Cat with Pancreatic Adenocarcinoma Treated with Surgical Resection and Toceranib Phosphate","volume":"6","author":"Todd","year":"2020","journal-title":"J. Feline Med. Surg. Open Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/1098612X211067023","article-title":"Low Dose Meloxicam Is Safe and Tolerable When Combined with Toceranib Phosphate in Cancer-Bearing Cats","volume":"24","author":"Keepman","year":"2022","journal-title":"J. Feline Med. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jsap.13217","article-title":"Squamous Cell Carcinoma of the Anal Sac in Two Cats","volume":"62","author":"Kopke","year":"2021","journal-title":"J. Small Anim. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/1098612X16638118","article-title":"Tolerability of Toceranib Phosphate (Palladia) When Used in Conjunction with Other Therapies in 35 Cats with Feline Oral Squamous Cell Carcinoma: 2009\u20132013","volume":"19","author":"Olmsted","year":"2017","journal-title":"J. Feline Med. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1098612X241256473","DOI":"10.1177\/1098612X241256473","article-title":"Evaluation of the Efficacy and Safety of Toceranib Phosphate in Cats with Macroscopic Mammary Adenocarcinoma","volume":"26","author":"Blackwood","year":"2024","journal-title":"J. Feline Med. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/vco.12211","article-title":"Retrospective Evaluation of Toceranib Phosphate (Palladia\u00ae) Toxicity in Cats","volume":"15","author":"Merrick","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_14","unstructured":"(2022, May 01). Lap of Love Pet Quality-of-Life Scale. Available online: https:\/\/www.lapoflove.com\/how-will-i-know-it-is-time\/lap-of-love-quality-of-life-scale.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jfms.2004.01.007","article-title":"Treatment of a Well Differentiated Pulmonary Adenocarcinoma in a Cat by Pneumonectomy and Adjuvant Mitoxantrone Chemotherapy","volume":"6","author":"Clements","year":"2016","journal-title":"J. Feline Med. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.12935\/jvma.70.52","article-title":"Long-term Treatment with Toceranib Phosphate in a Dog with Metastatic Primary Pulmonary Adenocarcinoma","volume":"70","author":"Tamura","year":"2017","journal-title":"J. Jpn. Vet. Med. Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1098612X16643124","article-title":"Toxicity and Response in Cats with Neoplasia Treated with Toceranib Phosphate","volume":"19","author":"Harper","year":"2017","journal-title":"J. Feline Med. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1098612X17695898","article-title":"Retrospective Evaluation of Toceranib Phosphate (Palladia) Use in Cats with Mast Cell Neoplasia","volume":"20","author":"Berger","year":"2018","journal-title":"J. Feline Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/03009858221122517","article-title":"Feline Pulmonary Carcinoma: Gross, Histological, Metastatic, and Immunohistochemical Aspects","volume":"60","author":"Santos","year":"2023","journal-title":"Vet. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.12951\/jvcs.1.8","article-title":"Clinical Findings in Lung-Digit Syndrome in Five Cats","volume":"1","author":"Sugiyama","year":"2010","journal-title":"J. Jpn. Vet. Cancer Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1098612X16634391","article-title":"Role of Thyroid Transcription Factor-1 in the Diagnosis of Feline Lung\u2013Digit Syndrome","volume":"19","author":"Finotello","year":"2017","journal-title":"J. Feline Med. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/0300985811419529","article-title":"Morphologic and Molecular Analysis of 39 Spontaneous Feline Pulmonary Carcinomas","volume":"49","author":"Yoon","year":"2012","journal-title":"Vet. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5858\/2003-127-193-IASOCT","article-title":"Incidence and Significance of Cytoplasmic Thyroid Transcription Factor-1 Immunoreactivity","volume":"127","author":"Bejarano","year":"2003","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1354\/vp.08-VP-0219-L-FL","article-title":"Immunohistochemical Expression of C-KIT Protein in Feline Soft Tissue Fibrosarcomas","volume":"46","author":"Smith","year":"2009","journal-title":"Vet. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1354\/vp.08-VP-0084-R-FL","article-title":"Expression of KIT Receptor in Feline Cutaneous Mast Cell Tumors","volume":"46","author":"Fondevila","year":"2009","journal-title":"Vet. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1354\/vp.41-4-371","article-title":"The Use of KIT and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors","volume":"41","author":"Kiupel","year":"2004","journal-title":"Vet. Pathol."}],"container-title":["Animals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2615\/16\/5\/839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:44:50Z","timestamp":1773063890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2615\/16\/5\/839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ani16050839"],"URL":"https:\/\/doi.org\/10.3390\/ani16050839","relation":{},"ISSN":["2076-2615"],"issn-type":[{"value":"2076-2615","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}